Needham analyst Quinn Bolton maintains MACOM Technology (NASDAQ:MTSI) with a Buy and raises the price target from $70 to $72.
Novartis Announced Kisqali Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those with Aggressive HR+/HER2- Advanced Breast Cancer
Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.
